Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines-Reference-Cited by-同舟云学术

Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines

Published:2013-09-24 Issue:294 Volume:6 Page:
ISSN:1945-0877
Container-title:Science Signaling
language:en
Short-container-title:Sci. Signal.

Author:

Niepel Mario¹,Hafner Marc¹,Pace Emily A.²,Chung Mirra¹,Chai Diana H.²,Zhou Lili¹,Schoeberl Birgit²,Sorger Peter K.¹

Affiliation:

1. Harvard Medical School Library of Integrated Network-based Cellular Signatures Center, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.

2. Merrimack Pharmaceuticals, Cambridge, MA 02139, USA.

Abstract

Activity of receptor tyrosine kinase networks may serve as an effective means to classify breast cancers and predict their sensitivity to therapeutic drugs.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference64 articles.

1. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

2. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

3. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

4. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

5. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computational precision therapeutics and drug repositioning;Comprehensive Precision Medicine;2024

2. Large-Scale Information Retrieval and Correction of Noisy Pharmacogenomic Datasets through Residual Thresholded Deep Matrix Factorization;2023-12-08

3. Triple immune modulator therapy for aberrant hyperinflammatory responses in severe COVID-19;Clinical Immunology;2023-06

4. Proteomic approaches in the study of cancers;Proteomics;2023

5. Disentangling ERBB Signaling in Breast Cancer Subtypes—A Model-Based Analysis;Cancers;2022-05-12